Novocure Advances Tumor Treating Fields Therapy for Cancer Treatment
Novocure, a global oncology company, continues to advance its Tumor Treating Fields (TTFields) therapy aimed at extending survival in aggressive cancer forms. TTFields are electric fields that target and kill cancer cells while sparing healthy cells. This innovative therapy has shown enhanced effects when combined with chemotherapy, radiotherapy, and other cancer treatments.
Novocure's TTFields are approved for treating adult patients with glioblastoma and malignant pleural mesothelioma in specific countries. The company is conducting clinical studies on TTFields for brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
The therapy is associated with some side effects, including skin irritation, allergic reactions, and potential infections at the contact site. Patients are advised to consult their healthcare providers regarding any adverse effects.
Headquartered in Root, Switzerland, Novocure has operational centers in Portsmouth, New Hampshire, and Tokyo, along with a research center in Haifa, Israel. The company is committed to expanding its global footprint and continues to explore new applications for TTFields therapy.
Share